Protea Biosciences Group, Inc. 4

Accession 0001144204-14-008810

CIK 0001335103operating

View on SEC.gov Company Profile

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 8:51 PM ET

Size

47.3 KB

Accession

0001144204-14-008810

Insider Transaction Report

Form 4

Period: 2006-06-07

Protea Biosciences Group, Inc.NONE

HOSTLER STANLEY

DirectorVice President and Secretary10% Owner

Transactions

Award
Stock Option
2013-03-22$120313.00/sh+218,750$26,318,468,750→ 4,472,682 total
Exercise: $0.55From: 2013-03-22Exp: 2023-03-22→ Common Stock (218,750 underlying)
Award
Stock Option
2013-03-31$2200.00/sh+4,000$8,800,000→ 4,476,682 total
Exercise: $0.55From: 2013-03-31Exp: 2023-03-31→ Common Stock (4,000 underlying)
Award
Stock Option
2013-04-30$2200.00/sh+4,000$8,800,000→ 4,480,682 total
Exercise: $0.55From: 2013-04-30Exp: 2023-04-30→ Common Stock (4,000 underlying)
Award
Stock Option
2013-05-31$2200.00/sh+4,000$8,800,000→ 4,484,682 total
Exercise: $0.55From: 2013-05-31Exp: 2023-05-31→ Common Stock (4,000 underlying)
Award
Stock Option
2013-06-30$2200.00/sh+4,000$8,800,000→ 4,488,682 total
Exercise: $0.55From: 2013-06-30Exp: 2023-06-30→ Common Stock (4,000 underlying)
Purchase
Warrant
2013-07-23$1442874.00/sh+1,311,704$1,892,623,597,296→ 5,800,386 total
Exercise: $1.10From: 2013-07-23Exp: 2018-07-23→ Common Stock (1,311,704 underlying)
Purchase
Warrant
2013-07-23$122357.00/sh+111,234$13,610,258,538→ 5,911,620 total
Exercise: $1.10From: 2013-07-23Exp: 2018-07-23→ Common Stock (111,234 underlying)
Purchase
Warrant
2013-07-23$938764.00/sh+853,422$801,161,850,408→ 6,765,042 total
Exercise: $1.10From: 2013-07-23Exp: 2018-07-23→ Common Stock (853,422 underlying)
Purchase
Warrant
2013-07-23$938764.00/sh+853,422$801,161,850,408→ 6,765,042 total(indirect: By Spouse)
Exercise: $1.10From: 2013-07-23Exp: 2018-07-23→ Common Stock (853,422 underlying)
Conversion
Convertible Note
2013-07-23$874469.00/sh−1,748,938$1,529,392,063,922→ 5,195,042 total
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Conversion
Convertible Note
2013-07-23$74156.00/sh−14,831$1,099,807,636→ 5,058,610 total
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Conversion
Convertible Note
2013-07-23$568948.00/sh−1,137,896$647,403,653,408→ 4,008,610 total
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Conversion
Convertible Note
2013-07-23$568948.00/sh−1,137,896$647,403,653,408→ 4,008,610 total(indirect: By Spouse)
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Award
Stock Option
2013-07-31$2200.00/sh+4,000$8,800,000→ 4,012,610 total
Exercise: $0.55From: 2013-07-31Exp: 2023-07-31→ Common Stock (4,000 underlying)
Award
Stock Option
2013-08-31$2200.00/sh+4,000$8,800,000→ 4,016,610 total
Exercise: $0.55From: 2013-08-31Exp: 2023-08-31→ Common Stock (4,000 underlying)
Award
Stock Option
2013-09-30$2200.00/sh+4,000$8,800,000→ 4,020,610 total
Exercise: $0.55From: 2013-09-30Exp: 2023-09-30→ Common Stock (4,000 underlying)
Award
Stock Option
2013-10-31$2200.00/sh+4,000$8,800,000→ 4,024,610 total
Exercise: $0.55From: 2013-10-31Exp: 2023-10-31→ Common Stock (4,000 underlying)
Award
Stock Option
2013-11-30$2200.00/sh+4,000$8,800,000→ 4,028,610 total
Exercise: $0.55From: 2013-11-30Exp: 2023-11-30→ Common Stock (4,000 underlying)
Award
Stock Option
2013-12-31$2200.00/sh+4,000$8,800,000→ 4,032,610 total
Exercise: $0.55From: 2013-12-31Exp: 2023-12-31→ Common Stock (4,000 underlying)
Award
Stock Option
2014-01-31$2200.00/sh+4,000$8,800,000→ 4,036,610 total
Exercise: $0.55From: 2014-01-31Exp: 2024-01-31→ Common Stock (4,000 underlying)

Footnotes (2)

[F1]On December 20, 2011, the Company issued promissory notes to the Reporting Person equal to $250,000. On April 16, 2012, the Company issued a promissory note equal to $240,000 to the Reporting Person and VirginiaChild. On September 25, 2012, the Company issued promissory notes equal to $288,216 to the Reporting Person and Virginia Child. On November 30, 2012, the Company issued promissory notes equal to $600,000 to the Reporting Person and Virginia Child. Each $2.00 of outstanding principal and accrued unpaid interest is convertible into one share of common stock . On March 22, 2013, the Company approved adjustment of conversion price of the notes from $2.00 to $0.50 per share. In accordance with Conversion Agreements, as of June 30, 2013 the $1,517,573 in principal and accrued unpaid interest were converted into common stock of the Company. In addition, the Company issued a 5-year warrant to each note holder to purchase 75% of the number of shares into which the notes converted.
[F2]Represents share of record owned by the Reporting Person's wife, Virginia Child.

Documents

1 file

4
v368594_4.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Protea Biosciences Group, Inc.

CIK 0001335103

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001335103

Filing Metadata

Form type: 4
Filed: Feb 12, 7:00 PM ET
Accepted: Feb 13, 8:51 PM ET
Size: 47.3 KB

View on SEC.gov